Meta-analysis of quinolone-theophylline interactions.
Several fluoroquinolones currently under investigation or on the market potentially interact with theophylline. In this study, meta-analysis methodology was used to evaluate the significance of findings from quinolone-theophylline interaction studies. Two major databases were searched: Index Medicus (from 1986 to March 1990) and Current Content/Clinical Medicine (from 1985 to March 1990). A total of 32 studies were retrieved; 20 of these met the inclusion criteria. With a large effect size (ES) value of 2.26, enoxacin is the strongest inhibitor of theophylline metabolism of this family. The fail-safe N value was 135, indicating that 135 studies enrolling an average of 8 patients and showing no interaction (i.e., ES = 0) would be required to lower the ES to the threshold value of 0.1, which we considered a priori to render the results nonsignificant. Other fluoroquinolones showed a degree of interaction that can be considered significant: ciprofloxacin (ES = 0.50, fail-safe N = 26), norfloxacin (ES = 0.31, fail-safe N = 10). Ofloxacin (ES = 0.13, fail-safe N = 4), lomefloxacin (ES = 0.12, fail-safe N = 2), and fleroxacin (ES = 0.06, fail-safe N = 2) provided the weakest evidence of interaction based on effect size and power. Among the fluoroquinolones studied, ofloxacin, lomefloxacin, and fleroxacin, when available, should be the fluoroquinolones of choice when the patient also is receiving theophylline.
Parent
M
M
Dept. Pharmacie, Hôpital St-François d'Assise, Québec, Canada.
LeBel
M
M
D002939:Ciprofloxacin / Q000494:pharmacology; D004347:Drug Interactions; D015365:Enoxacin / Q000494:pharmacology; D006801:Humans; D015201:Meta-Analysis as Topic; D015363:Quinolones / Q000494:pharmacology*; D013806:Theophylline / Q000378:metabolism*
D015363:Quinolones; D015365:Enoxacin; D002939:Ciprofloxacin; D013806:Theophylline